Merck's Q3 earnings call revealed a mixed picture, with solid operational performance and cost management offset by top-line pressures, including the loss of exclusivity for certain products and European austerity measures. Despite these challenges, the company raised the lower end of its 2010 EPS guidance range, citing strong performances from key brands and a robust late-stage pipeline. Management expressed confidence in its position regarding the ongoing REMICADE arbitration and highlighted the company's diversified portfolio and global presence as key strengths. 

[1]